Navigation Links
Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives
Date:12/7/2007

uld be exercised, and LIALDA should be used only if the benefits outweigh the risks. No information is available for patients with hepatic impairment.

LIALDA is generally well tolerated. The majority of adverse events in the double-blind, placebo-controlled trials were mild or moderate in severity. In clinical trials (n=535), the most common treatment-related adverse events with LIALDA 2.4g/day, 4.8g/day and placebo were headache (5.6 percent, 3.4 percent and 0.6 percent, respectively) and flatulence (4 percent, 2.8 percent and 2.8 percent, respectively). Pancreatitis occurred in less than 1 percent of patients during clinical trials and resulted in discontinuation of therapy with LIALDA.

Important Safety Information for PENTASA

PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.

PENTASA is generally well tolerated. In worldwide clinical trials (n>2100), the most common adverse events were diarrhea (3.4 percent), headache (2.0 percent), nausea (1.8 percent), abdominal pain (1.7 percent), dyspepsia (1.6 percent), vomiting (1.5 percent), and rash (1.0 percent). As with other mesalamine products, serious adverse events may occur. PENTASA is contraindicated in patients with a hypersensitivity to salicylates. Caution should be used in patients with impaired hepatic or renal function. Patients with pre-existing renal disease, increased BUN or serum creatinine, or proteinuria should be monitored during PENTASA therapy.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise th
'/>"/>

SOURCE Shire PLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide
2. Joint NJ/NY Rally for Addiction Recovery to Be Hub of Events Nationwide
3. Photo: Tanger Outlet Center Shoppers Nationwide can Choose Pink to Fight Breast Cancer
4. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
5. Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During America on the Move Week With the YMCA, September 22-29, 2007
6. NIH/NCI renews and extends nationwide license for Genomatix software and databases
7. 100 Black Men of America, Inc. and American Red Cross Sign National Agreement to Increase Diverse Outreach Nationwide
8. New Website Launches Healthy Vending in Schools Nationwide to Help Combat Childhood Obesity
9. First Nationwide Class Action Filed on Behalf of Consumers Who Purchased Topps E. Coli Contaminated Ground Beef
10. American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide
11. Nationwide independent Taser study results suggest devices are safe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Lower-Auto-Insurance.com has released a ... kit in a car for reducing the costs of an ... will also be able to get lower prices for their vehicle ... an important role in determining policy costs. Because of this, ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... from the University of Melbourne and La Trobe University have ... grains such as wheat and barley. With the stress being ... that this discovery would allow them to manipulate the fibre ... the production of beta-glucans, which is a major part of ...
... is to soon go on Phase I trial. It maybe ... Biocon, Ms.Kiran Mazumdar Shaw. ,Ms.Shaw was speaking ... Foundation(MDRF) on awards for innovation and R&D.// There are close ... to diabetes should always bear this in mind and develop ...
... underwent a successful life-changing operation in India and returned home ... being// overweight. ,David Rogers, 62, from Abbeydale, Worcestershire, ... for the double hip and knee replacements that he desperately ... was about 37 kg too heavy for the surgery. ...
... two new genes found with breast tumors can predict the ... In the report appearing in he April 1 issue of ... identify women at risk for an early relapse of breast ... previously discovered as a potential marker of relapse in hormone-receptor ...
... the peels of fruits and vegetables, which are thrown away ... better to have a second thought next time, when you ... and keeps you young. ,As reported in foodconsumer.org ... the United States to $2.7 billion in 2003. Top of ...
... have bettered among the teenagers and young adults (TYAs) in ... than in those where people have to pay for their ... system of health insurance for all, regardless of age, meant ... than they were in the USA. ,Prof ...
Cached Medicine News:Health News:Overweight Briton Underwent Successful Surgery In India Being Denied By NHS 2Health News:Easy Access To Healthcare Services Essential For Better Survival Rates 2Health News:Easy Access To Healthcare Services Essential For Better Survival Rates 3
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... 2007 - ImmunoGen, Inc.,(Nasdaq: IMGN), a biopharmaceutical company ... (TAP),technology, today announced that clinical findings for three,different ... are to be,reported at the 43rd American Society ... June 1-5, 2007 in Chicago, IL., Trastuzumab-DM1 (abstract ...
... 2007 - GTx, Inc., (NASDAQ:,GTXI) announced today that ... clinical trial of Ostarine(TM) and from the ongoing ... for the treatment of multiple side effects of ... upcoming 2007,Annual Meeting of the American Society of ...
Cached Medicine Technology:ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3
... third-generation immunoassay system combines continuous ... processing with a broad testing ... higher volume clinical laboratories to ... tests simultaneously, as well as ...
... ADVIA Centaur delivers a new ... provides the flexibility to integrate ... now and in the future. ... comprehensive disease-focused menu of immunoassays ...
... Synchron LXi 725 clinical system combines ... accurate immunoassay testing capabilities, innovative data ... a single platform. After tests are ... for optimal quality assurance. If reflex ...
...
Medicine Products: